Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rilparencel

Cell therapy · developed by Prokidney

Phase 3 Most advanced trial (none active)
PROK Developer
1 Registered trials

What is Rilparencel?

Rilparencel (Renal Autologous Cell Therapy, REACT) is an autologous cell therapy made from a patient's own kidney biopsy tissue and injected into the kidneys. It is being studied in chronic kidney disease and in type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy
Therapy area
Endocrine, Renal & urology
Developer
Prokidney (PROK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
B72T6TX3GS

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05286853 Phase 3 Type 2 Diabetes Mellitus Withdrawn PROK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Chronic Kidney DiseasesType 2 Diabetes Mellitus

More from Prokidney

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PROK page.

Follow PROK, the company behind Rilparencel

See PROK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PROK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.